Literature DB >> 7660138

Recovery by splenectomy in patients with relapsed thrombotic thrombocytopenic purpura and treatment failure to plasma exchange.

H G Höffkes1, F Weber, M Uppenkamp, P Meusers, C Teschendorf, T Philipp, G Brittinger.   

Abstract

Thrombotic thrombocytopenic purpura is a serious, potentially fatal disease, and conventional plasma exchange appears to be the best initial therapy. Following this approach, survival in 90% of patients is available. In patients with relapse and treatment failure to plasma exchange, splenectomy is recommended. The rationale for splenectomy and the relevant pathomechanisms involved are obscure. In the present paper two patients with TTP are reported who first responded to conventional treatment strategies but later relapsed. Resumption of previous therapy was not able to continuously maintain normal platelet levels. Thus, splenectomy was considered to be indicated. In contrast to former reports, repeated cycles of conventional plasma exchanges were performed until a transient steady state (12 hrs) of the platelet counts occurred. Then splenectomy was performed immediately and, in contrast to former reports, no reinstitution of treatment was necessary after splenectomy. In addition no postoperative complications (bleeding, neurologic impairment) have been observed. This favorable outcome might be due to the strategy of repeated conventional plasma exchange procedures. The follow-up shows now event free disease for 2 years.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7660138     DOI: 10.1055/s-2007-1000391

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  5 in total

Review 1.  Case series: splenectomy: does it still play a role in the management of thrombotic thrombocytopenic purpura?

Authors:  Luc Dubois; Daryl K Gray
Journal:  Can J Surg       Date:  2010-10       Impact factor: 2.089

2.  [Multi-organ involvement in recurrent Moschcowitz disease. Splenectomy as ultima ratio in a therapeutic dilemma?].

Authors:  A R Jakob; E Hiller
Journal:  Med Klin (Munich)       Date:  1998-10-15

3.  Thrombotic Thrombocytopenic Purpura Associated with Dermatomyositis.

Authors:  Zohra R Malik; Amir Shahbaz; Kashif Aziz; Zareen Razaq; Muhammad Umair; Issac Sachmechi
Journal:  Cureus       Date:  2018-08-20

4.  Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng; Sara K Vesely; Spero R Cataland; Paul Coppo; Brian Geldziler; Alfonso Iorio; Masanori Matsumoto; Reem A Mustafa; Menaka Pai; Gail Rock; Lene Russell; Rawan Tarawneh; Julie Valdes; Flora Peyvandi
Journal:  J Thromb Haemost       Date:  2020-09-11       Impact factor: 5.824

5.  Thrombotic Thrombocytopenic Purpura Associated with Myelodysplastic Syndrome.

Authors:  Zohra R Malik; Nassim Mokraoui; Zareen Razaq; Gabriela L Severiano; Arnaud Yanogo
Journal:  Cureus       Date:  2020-03-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.